The Society
More than 35,000 clinicians, scientists and allied health professionals from over 160 countries are part of the ERS community
Become an ERS member
Q: As Head of Assembly 13, what are you most looking forward to about this year’s ERS Congress?
This year in Vienna we will have a full scientific program of all the recent progress made in the field of pulmonary vascular diseases and pulmonary embolism. I am very happy to say that we received many outstanding abstracts this year on the topic which will be presented throughout Congress. As well as this, we will have a full educational program relating to this specialism starting with the postgraduate courses on Friday, followed by clinical cases and skill workshops over the rest of the event.
This year the Andre Cournand lecture and award will be received by a member of our Assembly. The Andre Cournand lecture will be presented on Monday morning in a symposium dedicated on the right ventricle. Since Andre Cournand received the Noble price award for the invention of the right heart catheterisation, I believe this award and lecture does credit to Cournand’s scientific inheritance.
Q: What in your opinion will be the hot topics for pulmonary vascular diseases?
From 08:30–10:00 on Tuesday you can attend the session ‘Hot topics in pulmonary hypertension’ which will cover the highlights of the World Symposium on Pulmonary Hypertension 2024, providing an update on many of the hot topics in this area.
Q: Tell us your top three picks from the Congress programme?
1. Symposium – New therapeutic approaches in the management of pulmonary embolism, including high risk pulmonary embolism
This symposium dedicated to the novel developments in the treatment of acute pulmonary embolism will provide an update about the ongoing trials in pulmonary embolism and what can be expected in the near future.
2. Pro-con debate – Cracking the clot: debates on the management of high-risk pulmonary embolism
This pro-con debate on the treatment of high risk PE patients will inform us how to make our treatment decisions in those patients.
3. Hot topic – The transforming growth factor-β superfamily: a treatment target in pulmonary arterial hypertension
A hot topic session on pulmonary hypertension will focus on the results of the most recent trials and future expectations in the field of treatment of pulmonary arterial hypertension with a special focus on the transforming growth factor-β superfamily.